Compare Stocks: TELO, PRLD, INDP, and SRZN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INDP Indaptus Therapeutics	$2.51 +5.9%	$2.02	$0.92 ▼ $5.96	$315.78M	0.97	836,926 shs	467,592 shs
PRLD Prelude Therapeutics	$3.89 +0.3%	$4.94	$1.15 ▼ $6.83	$309.64M	0.97	516,939 shs	341,648 shs
SRZN Surrozen	$29.69 +6.1%	$23.54	$11.39 ▼ $37.83	$324.74M	0.47	1.03 million shs	781,259 shs
TELO Telomir Pharmaceuticals	$1.12 -2.6%	$1.16	$0.89 ▼ $1.82	$79.09M	-0.31	149,423 shs	64,619 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INDP Indaptus Therapeutics	+5.91%	+5.46%	+20.67%	-4.56%	-42.69%
PRLD Prelude Therapeutics	+0.26%	+5.99%	-23.58%	-18.96%	+173.94%
SRZN Surrozen	+6.15%	+1.26%	+48.23%	+28.03%	+111.47%
TELO Telomir Pharmaceuticals	-2.61%	-5.08%	-8.20%	-8.94%	-32.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INDP Indaptus Therapeutics	$2.51 +5.9%	$2.02	$0.92 ▼ $5.96	$315.78M	0.97	836,926 shs	467,592 shs
PRLD Prelude Therapeutics	$3.89 +0.3%	$4.94	$1.15 ▼ $6.83	$309.64M	0.97	516,939 shs	341,648 shs
SRZN Surrozen	$29.69 +6.1%	$23.54	$11.39 ▼ $37.83	$324.74M	0.47	1.03 million shs	781,259 shs
TELO Telomir Pharmaceuticals	$1.12 -2.6%	$1.16	$0.89 ▼ $1.82	$79.09M	-0.31	149,423 shs	64,619 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INDP Indaptus Therapeutics	+5.91%	+5.46%	+20.67%	-4.56%	-42.69%
PRLD Prelude Therapeutics	+0.26%	+5.99%	-23.58%	-18.96%	+173.94%
SRZN Surrozen	+6.15%	+1.26%	+48.23%	+28.03%	+111.47%
TELO Telomir Pharmaceuticals	-2.61%	-5.08%	-8.20%	-8.94%	-32.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INDP Indaptus Therapeutics	1.00	Sell	N/A	N/A
PRLD Prelude Therapeutics	2.50	Moderate Buy	$8.75	124.94% Upside
SRZN Surrozen	2.71	Moderate Buy	$48.33	62.79% Upside
TELO Telomir Pharmaceuticals	2.25	Hold	$4.00	257.14% Upside

Current Analyst Ratings Breakdown

Latest TELO, PRLD, INDP, and SRZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00 ➝ $54.00
9/17/2026	TELO Telomir Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
9/17/2026	PRLD Prelude Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$12.00
9/17/2026	TELO Telomir Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$4.00
8/20/2026	SRZN Surrozen	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
8/20/2026	SRZN Surrozen	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
8/10/2026	SRZN Surrozen	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$44.00
7/29/2026	PRLD Prelude Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/28/2026	SRZN Surrozen	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/17/2026	INDP Indaptus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$1.40 per share	N/A
PRLD Prelude Therapeutics	$12.14M	25.57	N/A	N/A	$1.09 per share	3.57
SRZN Surrozen	$3.48M	99.05	N/A	N/A	($19.21) per share	-1.55
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.17 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INDP Indaptus Therapeutics	-$20.85M	-$6.33	N/A	N/A	N/A	N/A	-302.89%	-203.49%	11/17/2026 (Estimated)
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	11/11/2026 (Estimated)
SRZN Surrozen	-$242.03M	-$40.55	N/A	N/A	N/A	-2,885.33%	N/A	-93.62%	11/6/2026 (Estimated)
TELO Telomir Pharmaceuticals	-$10.41M	-$0.91	N/A	N/A	N/A	N/A	-102.70%	-90.75%	12/2/2026 (Estimated)

Latest TELO, PRLD, INDP, and SRZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/6/2026	Q3 2026	SRZN Surrozen	-$1.1039	N/A	N/A	N/A	$0.48 million	N/A
8/13/2026	Q2 2026	INDP Indaptus Therapeutics	-$1.57	-$0.02	+$1.55	-$0.02	N/A	N/A
8/13/2026	Q2 2026	TELO Telomir Pharmaceuticals	-$0.07	-$0.79	-$0.72	-$0.79	N/A	N/A
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
8/6/2026	Q2 2026	SRZN Surrozen	-$1.29	-$0.41	+$0.88	-$0.41	$0.47 million	$5.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INDP Indaptus Therapeutics	N/A	19.49	19.49
PRLD Prelude Therapeutics	N/A	4.07	4.07
SRZN Surrozen	N/A	12.14	12.14
TELO Telomir Pharmaceuticals	N/A	16.16	16.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INDP Indaptus Therapeutics	7.06%
PRLD Prelude Therapeutics	79.72%
SRZN Surrozen	66.57%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
INDP Indaptus Therapeutics	9.94%
PRLD Prelude Therapeutics	49.20%
SRZN Surrozen	31.74%
TELO Telomir Pharmaceuticals	16.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INDP Indaptus Therapeutics	5	133.24 million	120.00 million	Not Optionable
PRLD Prelude Therapeutics	79	79.80 million	40.54 million	Optionable
SRZN Surrozen	44	11.61 million	7.93 million	Not Optionable
TELO Telomir Pharmaceuticals	5	68.78 million	57.52 million	N/A

TELO, PRLD, INDP, and SRZN Headlines

Recent News About These Companies

Telomir Pharmaceuticals, Inc. announced that it has received $5.618228 million in funding

October 6, 2026 | marketscreener.comM

Telomir (NASDAQ: TELO) secures $5.6 million PIPE as DeJoria adds capital

October 6, 2026 | americanbankingnews.com

Telomir Raises PIPE Financing to Fund Oncology Trials

October 6, 2026 | tipranks.com

Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company

October 6, 2026 | globenewswire.com

Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing

September 29, 2026 | newsfilecorp.comN

Research shows Telomir-Zn might slow bone cancer in dogs

September 24, 2026 | msn.com

Experimental drug found to slow bone cancer cell growth in dog and human lab tests

September 23, 2026 | dvm360.comD

Maxim Initiates Telomir Pharmaceuticals at Buy With $4 Price Target

September 18, 2026 | marketscreener.comM

Telomir Publishes Data Validating Telomir-Zn For AMD Alongside Cancer Indications; Stock Up

September 17, 2026 | rttnews.com

Telomir-Zn Preclinical Data Highlight Retinal Regeneration Potential

September 17, 2026 | tipranks.com

Telomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)

September 17, 2026 | globenewswire.com

Telomir unveils new preclinical data for Telomir-Zn

September 14, 2026 | tipranks.com

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

September 14, 2026 | globenewswire.com

Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell?

August 12, 2026 | defenseworld.netD

Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models

August 10, 2026 | markets.businessinsider.com

Telomir-Zn Preclinical Data Support Advancement in TNBC

August 10, 2026 | tipranks.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer Models

August 10, 2026 | quiverquant.comQ

TELO Telomir Pharmaceuticals, Inc.

July 8, 2026 | seekingalpha.com

Telomir Pharmaceuticals Announces Peer-Reviewed Publication in Biomedicine & Pharmacotherapy Demonstrating Restoration of Insulin Sensitivity with Telomir-Zn in a Preclinical ...

June 15, 2026 | usatoday.com

Telomir Showcases Preclinical Telomir-Zn Diabetes Efficacy Data

June 15, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, PRLD, INDP, and SRZN Company Descriptions

Indaptus Therapeutics NASDAQ:INDP

$2.51 +0.14 (+5.91%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.45 -0.06 (-2.31%)

As of 10/9/2026 07:51 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Prelude Therapeutics NASDAQ:PRLD

$3.89 +0.01 (+0.26%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.90 +0.00 (+0.13%)

As of 10/9/2026 04:38 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Surrozen NASDAQ:SRZN

$29.69 +1.72 (+6.15%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$30.27 +0.58 (+1.96%)

As of 10/9/2026 07:30 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Telomir Pharmaceuticals NASDAQ:TELO

$1.12 -0.03 (-2.61%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.13 +0.01 (+0.89%)

As of 10/9/2026 07:30 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELO, PRLD, INDP, and SRZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELO, PRLD, INDP, and SRZN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELO, PRLD, INDP, and SRZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, PRLD, INDP, and SRZN Company Descriptions

Indaptus Therapeutics NASDAQ:INDP

Prelude Therapeutics NASDAQ:PRLD

Surrozen NASDAQ:SRZN

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELO, PRLD, INDP, and SRZN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELO, PRLD, INDP, and SRZN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELO, PRLD, INDP, and SRZN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TELO, PRLD, INDP, and SRZN Company Descriptions

Indaptus Therapeutics NASDAQ:INDP

Prelude Therapeutics NASDAQ:PRLD

Surrozen NASDAQ:SRZN

Telomir Pharmaceuticals NASDAQ:TELO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools